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SPACE PHARMACEUTICALS: WILL THE UNITED




SPACE, WITH ITS absence of vibration, near-perfect
vacuum, sterile environment, unfiltered sunlight, and
lack of significant gravitational fields, provides an envi-
ronment perfect for the production of pharmaceuticals.'
This environment allows pharmaceuticals to be produced
in higher quantities and more efficiently than on earth.2
For example, earth's gravity concentrates sediment and
other impurities during drug production, reducing yield
and purity. In the weightlessness of space this problem
does not exist, resulting in products with greater purity
and strength.
U.S. companies are already conducting pharmaceutical
production experiments in space. In one such experi-
ment, McDonnell Douglas produced a drug 716 times
more separated than could be produced on earth, while
obtaining five times greater purity.4 These positive re-
sults have led to predictions that space production will
revolutionize pharmaceutical development by enhancing
our ability to produce drugs of sufficient purity to help
IJonathan N. Goodrich et al., Pharmaceutical Production in Space? The Case of the
USA, 29 MED. Sci. L. 233 (1989).
2 Id.
3 Id.
4 David Osborne, Business in Space, ATLANTC MONTHLY, May 1985, at 45-53, 56-
58.
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fight many heretofore incurable diseases.5 As a result, us-
ing space as a laboratory for producing pharmaceuticals is
a major goal of U.S. pharmaceutical companies.
Despite the potential that space production holds for
the pharmaceutical industry, its development faces many
practical and legal obstacles. Practical obstacles include
the need for massive investment capital to establish space
facilities and conduct space research, foreign competition
by government subsidized firms, high insurance costs, 6
5 See Michael Schrage, Putting the Final Frontier in Perspective, WASH. POST, Feb. 2,
1990, at G3 (citing THE CENTER FOR SPACE POLICY, INC., COMMERCIAL SPACE IN-
DUSTRY IN THE YEAR 2000: A MARKET FORECAST 1-190 (1985)). A study by the
Center for Space Policy estimates that, given a suitable environment for develop-
ment, American companies could develop as much as $40 billion worth of
pharmaceuticals and microchips in space by the year 2000. Id.
6 Before risking massive capital investments in space pharmaceutical produc-
tion facilities, companies must procure space insurance, which is paid both on a
launch-by-launch basis, for property damage to the launch vehicle or spacecraft,
and also on an annual basis for commercial operating risk coverage and third
party liability coverage for injury or damage to others not associated with the
launch. Review of Latest U.S. Space Activities, 13 SATELLITE NEWS 44, 46 (1990).
Such insurance, however, is extremely expensive, and insurance rates are unstable
and subject to great fluctuation. Insuring Space-related Risks, Bus. INS., Sept. 30,
1991, at 37. Since 1990, industry claims total $490 million, resulting in current
rates as high as 16%-18% of the insured value. James R. Asker, U.S. Commercial
Space Revenues Projected to Hit $5 Billion in 1992, AVIATION WK. & SPACE TECH., June
29, 1992, at 68. With some 20 commercial launches scheduled between 1993 and
1995, potential losses are astronomical, adding great uncertainty to the future of
space insurance rates. Current high rates are not, however, the pharmaceutical
industry's only insurance problem. The typical insurance contract for a commer-
cial space launch covers three phases: (1) launch; (2) placement into initial orbit;
and (3) placement into final orbit coupled with a 180 day in-orbit testing period.
Space is a Risky Business, FLIGHT INT'L, June 12, 1991, at 25. Space-produced
pharmaceuticals require a fourth currently uncovered phase - successful return
to earth of the pharmaceuticals produced. The addition of a fourth phase of in-
surance coverage, with a variety of new risks, would further increase insurance
costs.
In addition to the problem of high rates, the availability of space insurance may
become a problem since the low number of insurable payloads and the potentially
high cost of a single loss requires that an insurance company stay in the market for
a long period of time before realizing a profit. Carissa Christensen &Joel Green-
berg, The Commercial Launch Industry: Will it Fly on its Own?, AEROSPACE AM., May
1992, at 32. The number of insurers willing to participate in the market might
increase, however, if a greater number of insurable payloads were available, assur-
ing profitability in a shorter period of time. The necessary number of payloads
would be available if government launches would move from self-insurance to
commercial insurance. This policy would be appropriate not only because of gov-
ernment participation in encouraging development of the commercial space in-
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and potential competition from lower cost earth-pro-
duced products.7 These risks, coupled with major legal
obstacles including the poor response of the U.S. Patent
Office to the need for greater protection for pharmaceuti-
cal patents,8 outdated Food and Drug Administration
(FDA) regulations, and the threat of liability under U.S.
antitrust law for participating in joint ventures necessary
to develop the industry,9 make the development of space
pharmaceuticals a high-risk, yet high-reward, proposition.
II. ANTITRUST
Due to the enormous capital expenditures required to
conduct space research and production, using space to
develop pharmaceuticals is beyond the reach of most indi-
vidual pharmaceutical companies. Conventional wisdom,
therefore, dictates that joint ventures are necessary to
raise the capital needed for space pharmaceutical devel-
opment.' 0 When U.S. firms enter into joint ventures,
dustry, but also because such a policy would be more economically efficient for
the government. Id.
7 Two other obstacles present themselves. First, and of primary concern, is the
question of whether the space pharmaceutical industry is profitable. Without an
acceptable return on investment there will be no financial incentive for pharma-
ceutical companies to invest in research and development or production. Good-
rich et al., supra note 1, at 238-39. A second major problem is the actual operation
of any space production facility. If humans are required to run the facilities, they
may be required to stay in space for an extended period of time. As a result, they
would face a number of potential health problems including bone decalcification
and deterioration due to weightlessness, loss of red blood cells, impairment of the
immune system, and cardiovascular de-conditioning. Id.
8 Since the pharmaceutical industry is highly competitive, the first to develop a
new drug is generally able to control the market for a period of time. Therefore,
proprietary protection is critical and must be assured because pharmaceutical
markets are huge; companies seldom develop new drugs unless anticipated sales
are more than $60 million per year. Patents in Space, 1989: Hearings on H.R. 2946
Before the Subcomm. on Courts, Intellectual Property and the Administration ofJustice of the
House of Representatives Comm. on the Judiciary, 101st Cong., 1st Sess. 50 (1989)
[hereinafter Patents in Space Hearings] (testimony of Dr. Charles Bugg, Director,
Center for the Commercial Development of Space, University of Alabama at
Birmingham).
9 Id.
1o There are three types of joint ventures: research, production, and distribu-
tion. PHILLIP AREEDA, ANTITRUST LAw 348 (1986); see Douglas H. Ginsburg, Anti-
trust, Uncertainty, and Technological Innovation, 24 ANTITRUST BULL. 635, 670 (1979)
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however, they risk antitrust liability. This risk of liability
arises because U.S. antitrust law places emphasis on
avoiding harmful market concentration and unfair trade
practices. These laws, which may have been appropriate
to regulate the domestic economy at the time enacted, are
no longer viable because U.S. firms now compete in a
global marketplace. To compete effectively, these firms
must be allowed to compete according to the norms of
that global marketplace. As only one of three major
global competitors, the United States cannot dictate the
rules governing global competition or survive unless it
plays by them.
While U.S. antitrust laws are based on principles of
competition, they also contain certain uniquely American
notions of "fair play" designed to protect small business
people. Additionally, the United States, because of its
highly decentralized economy, has turned to "self regula-
tion" to protect competition." These policies mandate
that courts and, to a greater or lesser extent depending
upon the current administration, the Justice Department
examine joint operations between competitors very
closely. The Japanese and the European Economic Com-
munity (EEC), on the other hand, take a different ap-
proach. The Japanese and the EEC view the protection of
competition as only one aspect of the government's re-
sponsibility in creating the most effective industrial pol-
icy.' 2 The main thrust of their antitrust laws is prevention
of monopolies and predatory practices. 13 This premise
underlies the attitudes of both the Japanese and the EEC
when applying antitrust law to research and development
(R&D) and production joint ventures. Therefore, when
competing with the United States, these countries often
encourage joint ventures to take advantage of efficiencies
("[A] joint venture can be seen as a partial rather than complete integration of two
firms, which preserves pro tanto their capacity to compete with respect to the por-
tion of their operations that is not integrated in the joint venture.").
1 H.R. REP. No. 516, 101st Cong., 2d Sess. 5 (1990).
2 Id.
1s Id.
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and economies of scale.14 Allowing U.S. firms to partici-
pate in joint ventures with the same freedom would allow
them to achieve the same efficiencies and economies of
scale, reduce risks through cost spreading, speed profita-
ble results, and open new markets with greater ease. 15
Despite these obvious benefits, joint ventures still raise le-
gitimate antitrust concerns as excellent vehicles for hiding
illegal price fixing, output restrictions, and monopolies. 6
A. THE JAPANESE
Japan greatly influences the norms of conducting global
high technology competition. The key to Japan's interna-
tional competitiveness is a strong government-business
relationship that has greatly increased the ability of Japa-
nese firms to spread the risk of high technology joint ven-
tures. One half of this relationship is the Keiretsu,17 and
the other half is the Ministry of International Trade and
Industry (MITI)."a By coordinating the resources of gov-
ernment and industry, the MITI and the Keiretsu couple
'4 Alvin F. Lindsay III, Comment, Tuning in to HDTV: Can Joint Production Ven-
tures Improve America's High-Tech Picture?, 44 U. MIAMI L. REv. 1159 (1990).
15 Id. at 1165.
16 Id. at 1166.
17 Keiretsu (Kay-rhet-sue) translates into "business alliance." Of the six major
horizontal Keiretsu in Japan, three were formed from pre-World War II family-
owned industrial groups known as Zaibatsu, and three were formed around major
banks. The Keiretsu are conglomerates of companies that conduct a variety of
businesses. These alliances employ cross holding of shares, presidential counsels,
intra-group financing by common banks, mutual appointment of officers, and
joint investments in new industries. The six major horizontal Keiretsu are Mitsub-
ishi, Mitsui, Sumitomo, Fuyo, DKB, and Sanwa. Almost all of these companies
operate in the following industries: financial services; computers and electronics;
automobiles; trading and retail; food and beverages; construction; metals; real es-
tate; oil and coal; rubber and glass; chemicals; fibers and textiles; pulp and paper;
mining and forestry; industrial equipment; cameras and optics; cement and ship-
ping; and transportation. Carla Rapoport, Why the Japanese Keep on Winning, FOR-
TUNE, July 15, 1991, at 77, 81, 84.
1s The prime mover behind industrial targeting is the MITI. The MITI's direc-
tor freely admits supporting industry attempts to target specific industries or tech-
nologies and justifies such action by stating, "Without the development of
technology, we can't assure the progress of living standards. This kind of technol-
ogy development doesn't pay in the short term, so we have to support it." Id. at
84.
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investment capital with high technology. The combina-
tion, aided by Japan's lax enforcement of its antitrust
laws, has enabled Japan to capture world leadership in
electronic products, automobiles, and computer chips.
This success was due, at least in part, to the ability ofJap-
anese firms to spread the risk of high technology
ventures. 19
1. Targeting
Like the electronics and automobile industries before
government intervention, Japan's pharmaceutical industry
is in its infancy.20 The Japanese government, however,
has begun attempts to stimulate pharmaceutical R&D by
amending Japanese patent law to provide better protec-
tion for pharmaceuticals and beginning a program of dis-
criminatory pricing against older drugs to stimulate the
production of new ones. 2 ' These governmental actions
indicate a growing interest in developing a global phar-
maceutical industry, thereby increasing the likelihood of
direct government involvement.
Japanese industrial powers also appear to be moving
into the pharmaceutical industry. Most significant is the
apparent move by the Japanese steel industry into
pharmaceuticals. 22 Companies such as NKK Corp., Nip-
pon Steel, and Kobe Steel, all owned by the Keiretsu, are
investing capital and diversifying into pharmaceuticals,
and it is anticipated that they too will turn to joint ven-
'9 The MITI's activities include developing Japan's fully integrated electronics
industry. Between 1961 and 1981, estimates indicate that the Japanese govern-
ment provided $6 billion to computer makers and used government facilities to
develop semi-conductors for the industry. As a result, Japan was able to effec-
tively compete in the world market by 1980 despite the poor state of their elec-
tronics industry only 20 years before. Id.
20 Currently over 6000 chemical and pharmaceutical companies exist in Japan;
however, these firms are generally too small to be global competitors or to invest
in space R&D. Emma Chynoweth, The Western Influence: Multinationals Mount a
Steady Drive, CHEMICAL WK., Nov. 27, 1991, at 40.
21 W. CARL KESTER, JAPANESE TAKEOVERS: THE GLOBAL CONTEST FOR CORPO-
RATE CONTROL 145 (1991).
22 Edmund Klamann, Steel Makers Test New Waters in Biotech Industry, CHEMICAL
WK., Aug. 24, 1991, at 8.
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tures involving other firms or the government to gain a
competitive edge.25  Although experts disagree on the
Japanese' ability to produce new products sufficient for
global exploitation, Japan is a leader in discovering new
chemical products, and its products get to market faster
than products in the United States.24 As demonstrated by
the losses in the U.S. semi-conductor industry in the mid-
1980s to Japanese competition, the domination of the
U.S. video cassette recorder (VCR) market by the Japa-
nese, and the threatened loss of the new High Definition
Television (HDTV) market, U.S. firms can currently do
little but fall victim to the Japanese high technology
steamroller. Japan now appears to be turning that steam-
roller toward the world pharmaceutical markets. This
market will, in the coming years, necessarily include the
high technology development of space pharmaceuticals,
an ideal venture for Keiretsu/MITI exploitation.
2. Antitrust Laws
Japan's primary antitrust law is the Act Concerning the
Prohibition of Private Monopoly and Maintenance of Fair
Trade 25 (Anti-Monopoly Act) enacted during the Allied
Occupation of Japan after World War II. The Anti-Mo-
nopoly Act was modeled on U.S. antitrust law, but recent
Japanese policies encouraging R&D and production joint
ventures through tax incentives, government financial
support, and relief from antitrust laws, have relaxed its
restrictions.26
Although the Japanese antitrust law appears similar to
U.S. law, there is little similarity in reality. Enforcement
23 Id.
24 Lois Gaeta, Japanese Pharmaceutical Industry Gets Ready for U.S. Market, MED.
MARKETING & MEDIA, Apr. 1991, at 19.
25 Shiteki dokusen no kinshi oyobi Kosei Torihiki no Kakuho ni kansuru
Horitsu, Act No. 54, 1947, translated in HIROSHI IYORI & AKINORI UESUGI, THE
ANTIMONOPOLY LAws OF JAPAN 213-64 (1983) [hereinafter Anti-Monopoly Act].
26 H. R. REP. No. 516, supra note 11, at 6. This relaxation represents a return to
the pre-war arrangement in Japan as illustrated by the Key Industries Control Law
of 1931, which was designed to increase market concentration in key industries.
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of the Anti-Monopoly Act rests with the Japanese Fair
Trade Commission (JFTC), 2 7 which wields quasi-judicial
and quasi-legislative power.28 Although theJFTC has the
power to bring both criminal and civil actions, civil penal-
ties are inconsequential, including only consent decrees, 29
cease-and-desist orders, 30 and surcharges on gross earn-
ings, 3' while criminal actions are virtually non-existent.
TheJFTC has pursued only six criminal actions since pas-
sage of the Anti-Monopoly Act.32 Additionally, although
the Anti-Monopoly Act, like U.S. antitrust law, gives a pri-
vate right of action, 33 private plaintiffs are rare. Since pas-
sage of the Anti-Monopoly Act, only seven plaintiffs have
filed actions for damages, and no one has prevailed in a
Japanese court. 4
The non-enforcement ofJapanese antitrust law makes it
necessary for U.S. pharmaceutical companies who aspire
to compete in the coming race for space pharmaceuticals
to receive immediate antitrust exemptions for joint ven-
tures to allow risk-spreading commensurate with that en-
joyed by the Japanese. The Japanese are on the move in
the global pharmaceutical market and, if history is any in-
dicator, this move is being accomplished by agreement
between the Keiretsu and the MITI whose deals have never
been prohibited by the JFTC.35
B. EUROPEAN ECONOMIC COMMUNITY
The European Economic Community (EEC), like the
Japanese, promotes the creation of high technology in-
dustries and has done so by significantly adjusting its anti-
27 Anti-Monopoly Act, supra note 25, § 89.
28 Preston Moore, Antitrust Aspects of Technology Exploitation in Japan, in INTERNA-
TIONAL ANTITRUST 32.031, 32.035 (William A. Hancock ed., 1991).
29 Anti-Monopoly Act, supra note 25, § 48.
30 Id. § 54.
31 Id. § 7-2.
32 See J. Mark Ramseyer, The Costs of the Consensual Myth: Antitrust Enforcement and
Institutional Barriers to Litigation in Japan, 94 YALE L.J. 604, 616 (1985).
23 Anti-Monopoly Act, supra note 25, § 34.
3 See Ramseyer, supra note 32, at 617.
25 KESTER, supra note 21, at 97.
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trust laws to encourage R&D and production joint
ventures. The EEC antitrust law is contained in article 85
of the Treaty of Rome. 36 Generally, article 85(1) prohib-
its agreements that restrict competition within the EEC, 7
and article 85(2) makes void any agreement falling within
the definition of article 85(1).38 Parties may, however, re-
quest exemptions under article 85(3) from the Commis-
sion of the European Community (Commission). 3
Because the Commission holds the exclusive right to
grant exemptions under article 85, it controls, for all prac-
-6 Treaty Establishing the European Economic Community, Mar. 25, 1957, art.
85, 298 U.N.T.S. 11, 47 [hereinafter Treaty of Rome].
-7 Id. Article 85(1) of the Treaty of Rome provides that:
the following shall be prohibited as incompatible with the common
market: all agreements between undertakings, decisions by associa-
tions of undertakings and concerted practices which may effect trade
between Member States and which have as their object or effect the
prevention, restriction or distortion of competition within the com-
mon market, and in particular those which:
(a) directly or indirectly fix purchase or selling prices or any other
trading conditions;
(b) limit or control production, markets, technical development, or
investment;
(c) share markets or sources of supply;
(d) apply dissimilar conditions to equivalent transactions with other
trading parties, thereby placing them at a competitive disadvantage;
(e) make the conclusion of contracts subject to the acceptance by
other parties of supplementary obligations which, by their nature or
according to commercial usage, have no connection with the subject
of such contracts.
Id.
5 Id. Article 85(2) states: "Any agreements or decisions prohibited pursuant to
this Article shall be null and void." Id.
' Id. Article 85(3) provides that: the provisions of article 85(1) may be de-
clared inapplicable in the case of:
- any agreement or category of agreements between undertakings
- any decision or category of decisions
- any concerted practice or category of concerted practices; which
contributes to improving the production or distribution of goods or
to promote the technical or economic progress, while allowing con-
sumers a fair share of the resulting benefit, and which does not:
(a) impose on the undertaking concerned restrictions which are not
indispensable to the attainment of these objectives;
(b) afford such undertakings the possibility of eliminating competi-
tion in respect of a substantial part of the products in question.
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tical purposes, antitrust enforcement in the EEC.4" In
1984, the Commission adopted Commission Regulation
(EEC) 418/85 concerning block exemptions for R&D
joint ventures.4' The regulation gives automatic exemp-
tions for three types of R&D joint ventures: (1) joint R&D
coupled with joint exploitation of results; (2) joint ex-
ploitation of prior R&D results; and (3) joint R&D without
joint exploitation of results for agreements falling within
the scope of article 85(1).42 Joint exploitation under the
regulation includes joint manufacturing and licensing, but
not joint distribution or selling.43 EEC pharmaceutical
companies can, therefore, engage in both R&D joint ven-
tures and production joint ventures secure in the knowl-
edge that compliance with the detailed guidelines of the
Regulation insulates them from antitrust liability. The
Commission is currently considering further relaxation of
its competition rules governing production joint
ventures .
C. UNITED STATES
In comparison to their Japanese competitors, who face
no joint venture limitations because of lax enforcement of
Japanese antitrust laws, and EEC competitors, who have
detailed guidelines allowing predictable enforcement of
EEC antitrust laws, U.S. firms face both enforced and un-
predictable antitrust laws. The Sherman Act, which states
that "any contract or combination ... in restraint of trade
... is declared illegal," '45 is the primary antitrust legisla-
tion impeding the development of joint ventures in the
40 See Sara G. Zwart, Innovate, Integrate and Cooperate: Antitrust Changes and Chal-
lenges in the United States and the European Economic Community, 1 UTAH L. REV. 63, 83
(1989).
41 Commission Regulation (EEC) 418/85 of 19 December 1984 on the Applica-
tion of Article 85(3) of the Treaty to Categories of Research and Development
Agreements, 1985 O.J. EUR. COMM. LEGISLATION (L 53) 5 (Feb. 22, 1985).
42 Id. at 1.l(a)-(c).
43 Id. at 1.2(d).
44 138 CONG. REC. S2482 (daily ed. Feb. 27, 1992) (letter from the Commission
of the European Communities to the Honorable Frank Brown).
45 15 U.S.C. § 1 (1988). Section 1 states: "Every contract, combination in the
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United States.46 Additionally, pharmaceutical companies
probably cannot form corporations to conduct joint R&D
or production in space because of the Clayton Act's prohi-
bition against acquisitions lessening competition or creat-
ing monopolies.4 ' These laws, and their attendant treble
damages provisions, place U.S. high technology firms at a
competitive disadvantage internationally when compared
with both Japanese and EEC firms. Recognizing this
problem, Congress enacted the National Cooperative Re-
search Act of 1984 (NCRA).48  The NCRA continues the
steps began in the 1918 Webb-Pomerene Act 49 of helping
U.S. companies compete in the international arena by
protecting them from unfair competition by foreign firms
not restricted by U.S. antitrust laws.
1. National Cooperative Research Act of 1984
In interpreting the Sherman Act, U.S. courts developed
two tests to determine legality under section one: the
"per se test" and the "rule of reason." Under the "per se
test," combinations are illegal per se and "are not evalu-
ated in terms of their purpose, aim or effect." 50 Under
the "rule of reason," the alleged combination is judged
form of trust or otherwise, or conspiracy, in restraint of trade or commerce among
the several states, or with foreign nations, is declared illegal." Id.
46 Since section one of the Sherman Act is a broad statement, the development
of the contours of antitrust law under it has been left to the courts.
47 15 U.S.C. § 18 (1988). Section 18 provides:
No person engaged in commerce or any activity affecting commerce
shall acquire, directly or indirectly, the whole or any part of the stock
or other share capital and no person subject to the jurisdiction of the
Federal Trade Commission shall acquire the whole or any part of the
assets of another person engaged also in commerce or in any activity
effecting commerce, where in any line of commerce or in any activity
effecting commerce in any section of the country, the effect of such
acquisition may be to substantially lessen competition, or to tend to
create a monopoly.
Id.
48 15 U.S.C. §§ 4301-4305 (1988 & Supp. 1991).
49 15 U.S.C. §§ 61-65 (1988). The Webb-Pomerene Act exempted any "associ-
ation entered into for the sole purpose of engaging in export trade" from the
requirements of the Sherman Act. Id. § 62.
-0 United States v. Socony-Vacuum Oil Co., 310 U.S. 150, 228 (1940).
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"taking into account all relevant facts affecting competi-
tion in properly defined, relevant ...markets."15' The
NCRA provides U.S. R&D joint ventures a measure of re-
lief from the unpredictability of U.S. antitrust laws in two
ways .52
The first and most significant NCRA protection regard-
ing R&D joint ventures is the codification of the "rule of
reason" as the appropriate standard for testing the legal-
ity of an R&Djoint venture under section one of the Sher-
man Act.53 This codification ensures judicial certainty
previously missing from the Supreme Court's treatment
of antitrust suits. 54 Assuring pharmaceutical companies
that joint ventures will not be held to be per se illegal and
affording courts the flexibility to examine all relevant fac-
tors provides a significant measure of protection for R&D
joint ventures. This still leaves U.S. joint ventures at risk,
however, because applying the "rule of reason" only as-
sures them that they can avoid a plaintiffs motion for
summary judgment and does nothing to protect them at
51 PHILLIP AREEDA & Louis KAPLOWS, ANTITRUST ANALYSIS 273 (1988).
52 To qualify for NCRA protection, members of a R&D joint venture must file
written notification with the Attorney General and the Federal Trade Commission
(FTC) disclosing the identity of the members and the nature and objectives of the
joint venture. Although that information becomes public record, the NCRA at-
tempts to protect the R&D secrets of the joint venture by mandating that informa-
tion received pursuant to any antitrust investigation and any other information
received pursuant to the reporting requirements of the NCRA are immune from
governmental disclosure requirements under the Freedom of Information Act, 5
U.S.C. § 522 (1988). 15 U.S.C. § 4305 (1988).
5' 15 U.S.C. § 4302 (1988). Section 4302 states:
In any action under the antitrust laws, or under any State law similar
to the antitrust laws, the conduct of any person in making or per-
forming a contract to carry out a joint research and development
venture shall not be deemed illegal per se; such conduct will be
judged on the basis of its reasonableness, taking into account all rel-
evant factors affecting competition, including, but not limited to, ef-
fects on competition in properly defined, relevant research and
development markets.
Id.
See NCAA v. Board of Regents, 468 U.S. 85 (1984) (rule of reason applied in
antitrust case); United States v. Topco Assocs. Inc., 405 U.S. 596 (1972) (per se
rule applied to distribution joint venture analysis on a Sherman Act charge);
United States v. Penn-Olin Chem. Co., 378 U.S. 158 (1964) (standard of reasona-
bleness applied to production joint venture analysis on a Sherman Act charge).
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trial. When this is compared with the environment of
legal certainty enjoyed by Japanese and EEC firms who
know that their actions will not create antitrust liability,
U.S. participants in joint ventures bear a much greater in-
vestment risk.
The second significant provision of the NCRA allows
R&D joint ventures to shield themselves from treble dam-
ages by complying with the NCRA registration require-
ments. The NCRA limits an antitrust plaintiff's recovery
to actual damages, interest, and attorney fees and ex-
pressly denies recovery of treble damages under section
four of the Clayton Act 55 or under any similar applicable
state law.56 Additionally, the NCRA expressly allows any
joint venture that successfully defends against an antitrust
claim to recover reasonable attorney fees.57
Although the NCRA offers some protection to joint
ventures, it is worthless to the space pharmaceutical in-
dustry because it does not fully extend protection to pro-
duction joint ventures.58  Unlike some other high
technology industries in which the market prohibitive cost
55 15 U.S.C. § 15 (1988).
15 U.S.C. § 4303 (1988).
57 Id.
58 The NCRA, as codified in 15 U.S.C. § 4301, narrowly defines the type of
joint venture that receives its protection, excluding production joint ventures.
Subsection 6(a) of § 4301 states:
The term "joint research and development venture" means any
group of activities, including attempting to make, making, or per-
forming a contract, by two or more persons for the purpose of-
(A) theoretical analysis, experimentation, or systematic study of
phenomena or observable facts,
(B) the development or testing of basic engineering techniques,
(C) the extension of investigative findings or theory of scientific or
technical nature into practical application for experimentation
or demonstration purposes, including the experimental produc-
tion and testing of models, prototypes, equipment, materials,
and processes,
(D) the collection, exchange, and analysis of research information,
or
(E) any combination of the purposes specified in paragraphs (A),
(B), and (D), and may include the establishment and operation
of facilities for the conducting of research, the conducting of
such venture on a protected or proprietary basis, and the prose-
cuting of applications for patent and the granting of licenses for
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is the R&D and not the production phase, the space phar-
maceutical industry finds market prohibitive costs at both
the R&D and the production phases. Without this type of
antitrust protection for production joint ventures, phar-
maceutical companies will be effectively prevented from
developing sufficient space pharmaceuticals to compete in
the global market place.
2. Amending the NCRA
Recognizing the NCRA's shortcomings, Congress be-
gan moving toward extending NCRA protection to pro-
duction joint ventures in 1990.59 Congress is currently
considering two separate amendments to the NCRA: one
sponsored by Senator Strom Thurmond of South Caro-
lina,60 and one sponsored by Senator Patrick Leahy of
the results of such ventures, but does not include any activity
specified in subsection (b) of this section.
Id. § 4301(6)(a). Subsection (6)(b) states:
The term "joint research and development venture" excludes the
following activities involving two of more persons:
(1) exchanging information among competitors relating to costs,
sales, profitability, prices, marketing, or distribution of any
product, process, or service that is not reasonably required to
conduct the research and development that is the purpose of
such venture,
(2) entering into any agreement or engaging in any other conduct
restricting, requiring, or otherwise involving the production or
marketing by any person who is a party to such venture of any
product, process, or service other than the production or mar-
keting of proprietary developed through such venture, such as
patents and trade secrets, and
(3) entering into any agreement or engaging in any other conduct-
(A) to restrict or require the sale, licensing, or sharing of inven-
tions or developments not developed through such venture,
or
(B) to restrict or require participation by such party in other re-
search and development activities, that is not reasonably re-
quired to prevent misappropriation of proprietary
information contributed by any person who is a party to
such venture or of the results of such venture.
Id. § 4301(6)(b).
See The Bureau of National Affairs, Bush Administration Unveils Proposal to En-
courage Production Joint Venture, 7 INr'L TRADE REP. 699, 699 (1990).
- S. 1163, 102d Cong., 1st Sess. (1991).
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Vermont.61 These bills, entitled the Cooperative Produc-
tion Act of 1991 (Production Act) and the National Coop-
erative Research Act Extension of 1991 (Research Act
Extension) respectively, would extend NCRA protection
to production joint ventures.62
Currently, the Research Act Extension, passed by a vote
of 96 to 1 in the Senate63 and forwarded to the House of
Representatives for concurrence in March of 1992,1 ap-
pears to be the bill with the greatest chance of amending
the NCRA. The Bush Administration, however, had op-
posed the Research Act Extension in favor of the Produc-
tion Act because the Research Act Extension requires
that, in order to obtain protection, a company must: (1)
provide substantial benefits to the U.S. economy; or (2)
have its principle facilities for production located in the
United States or a third country whose law accords na-
tional treatment to U.S. companies conducting joint ven-
ture production.65 In contrast, the Production Act
provides national treatment for all companies under its
terms.66 These discriminatory requirements, at least ac-
cording to the Bush Administration, would both violate a
number of international agreements to which the United
States is a party67 and also hamper attempts to open new
markets for U.S. investment and trade. It is unclear at the
time of this writing 68 what position the Clinton Adminis-
tration will take on this issue; however, despite strong bi-
partisan support for the Research Act Extension,69
Senator Howard Metzenbaum, Democrat from Ohio and
Chairman of the Senate Judiciary Committee's Antitrust,
61 S. 479, 102d Cong., 1st Sess. (1991).
62 S. 1163 and S. 479 would strike the NCRA language in section 2, subsection
2, which states "joint research and development venture," replacing it with "joint
research, development, and production venture."
63 138 CONG. REC. S2457 (daily ed. Feb. 27, 1992).
138 CONG. REC. H875 (daily ed. Mar. 3, 1992).
6- 138 CONG. REc. S2481-82 (daily ed. Feb. 27, 1992).
S. 1163, 102d Cong., 1st Sess. (1991).
67 138 CONG. REc. S2482 (daily ed. Feb. 27, 1992).
68 December, 1992.
6 138 CONG. REC. S2482 (daily ed. Feb. 27, 1992).
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Monopolies, and Business Rights Subcommittee, strongly
opposes the Research Act Extension. 70  This raises seri-
ous doubts as to this bill's future viability.
3. Traditional Antitrust Analysis Applied to Joint Ventures
As stated, antitrust enforcement involving R&D and
production joint ventures is an uncertain area of the law.'
The NCRA resolves some of this uncertainty for regis-
tered R&D joint ventures but does nothing for production
joint ventures. If courts apply the "per se test," produc-
tion joint ventures are doomed. However, even if the
courts apply the "rule of reason" standard, the future of
both R&D and production joint ventures is still less than
certain. These uncertainties present risks that will materi-
ally affect investment decisions and likely retard growth in
the industry.
At the threshold, joint operations between pharmaceu-
tical companies must be truly joint ventures as opposed to
mere agreements to collaborate on price or market con-
trol of new pharmaceuticals developed.72 Permissible
joint ventures could include purely contractual collabora-
tions, such as horizontal information exchanges, joint
ownership and use of existing assets, or joint creation of
new enterprises to conduct manufacturing.73 Because
joint ventures are the only commercially practical way for
the United States to develop space-produced
pharmaceuticals, courts and federal agencies must care-
fully weigh both their competitive and anti-competitive ef-
70 138 CONG. REC. S2483 (daily ed. Feb. 27, 1992).
7, Robert Pitofsky, A Framework for Antitrust Analysis ofJoint Ventures, 74 GEo. L.J.
1605, 1605 (1986). Dean Pitofsky states that "[b]usiness complaints about the
inadequacy of antitrust policy seem particularly valid in this area of law, not so
much because the enforcement agencies or courts have made erroneous enforce-
ment decisions, but because uncertainties in enforcement policy have almost cer-
tainly blocked, delayed, or raised the cost of legitimate undertakings." Id.
72 Id. Generally, when a joint venture involves no integration of existing re-
sources and no creation of new productive capacity, it creates no new efficiencies
and, therefore, would be declared anti-competitive and illegal. Id.
73 Id. at 1606.
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fects when determining their impact on competition in the
relevant geographic and product market.
4. The Relevant Product Market74
How courts and federal agencies will scrutinize pharma-
ceutical joint ventures depends in part on how the space-
produced pharmaceutical industry is characterized. If
space-produced pharmaceuticals are characterized as new
products, these joint ventures are likely to be found
legal. 75 An example of this type of antitrust analysis ap-
pears in Broadcast Music, Inc. v. Columbia Broadcasting System,
Inc., where the Supreme Court refused to apply the "per
se test" blindly to a price-fixing situation involving blan-
ket licensing agreements. 76 Under the licensing agree-
ments scrutinized by the Court, the American Society of
Composers, Authors and Publishers (ASCAP) and Broad-
cast Music, Inc. (BMI) were able to set prices for blanket
use licenses covering musical works whose performance
rights ASCAP and BMI controlled. Although this
amounted to pricing by agreement rather than by market
forces, the Supreme Court held that the agreement did
not per se violate section one of the Sherman Act.77 The
Court reasoned that the blanket licenses were the only
practical way the industry could operate and that the li-
censing agreements were, to some extent, different prod-
ucts than the underlying performance rights they
represented.78 Stating that individual music producers
could not compete with the blanket licenses holders, the
Court refused to apply the per se test.79
A similar analysis can be applied to space pharmaceuti-
cals. Traditionally, in joint ventures where the parties are
already competing in a market, the parties argue with lit-
14 The relevant geographic market is assumed to be the entire United States for
simplification of the analysis.
75 Pitofsky, supra note 71, at 1609.
76 441 U.S. 1, 17 (1979).
77 Id. at 24.
78 Id. at 21-22.
79 Id. at 23.
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tle success that the pro-competitive effects of increased ef-
ficiency and earlier market expansion justify any anti-
competitive effect of the joint venture.8 0 The develop-
ment of space pharmaceuticals can be distinguished from
the traditional case. These high technology cases involve
developing products so technologically advanced that
they represent new products even though their sales im-
pinge upon an existing market. Even without giving
credence to arguments that joint ventures of space
pharmaceuticals will move up the date at which they be-
come available to the U.S. market, one hopes that the
courts will reach this conclusion and not stifle an industry
that would otherwise support U.S. economic interests.
However, because these pharmaceuticals will supplant ex-
isting pharmaceuticals, they may also be characterized as
competing products and be subjected to a more tradi-
tional antitrust analysis.
5. Pro-Competitive Effects
A key threshold consideration is that space-produced
pharmaceuticals are an extremely expensive venture. Al-
lowing joint ventures will allow firms to pool limited re-
sources without abandoning their independent corporate
structures. 8' This pooling allows the efficiencies of inte-
gration without the loss of competition in other segments
of the pharmaceutical industryq 2 Additionally, such com-
binations will create a new segment of the industry that
will increase U.S. market power in the international phar-
maceutical market. This will increase competition while
substantially enhancing the quantity and quality of drugs
available to combat a variety of diseases. Also, allowingjoint ventures will permit participating firms the greater
management control and flexibility needed because of the
speculative nature of these types of joint ventures. 83 Al-





lowing for the maximum possible management flexibility
will enhance the joint venture's future development and
avoid the need to anticipate and provide for all future
problems and contingencies at the joint venture's crea-
tion, a problem that would have to be resolved if the ven-
ture were formed on a contractual basis.8 4 The pro-
competitive effects of space pharmaceutical joint ventures
must, however, be balanced against the anti-competitive
effects.
6. Anti-Competitive Effects
There are four recognized anti-competitive concerns
regarding joint ventures that are relevant to the pharma-
ceutical industry. The magnitude of each of these factors
must be examined on a case-by-case basis. These anti-
competitive concerns include: (1) potential reductions in
competition; (2) the threat of one or both original parties
stifling future growth of the joint venture, or of the other
party to the venture, for their own benefit; (3) "spill-over"
effects regarding competition between the original parties
to the joint venture; and (4) collateral restrictive agree-
ments between the parties to the joint venture.8 5
In applying the traditional antitrust analysis to joint
ventures, courts are primarily concerned that joint ven-
tures will diminish competition.86 The fact that entities in
any joint venture historically competed independently
suggests that collaboration is unnecessary to overcome
entry barriers to the industry. 7  The over-arching ques-
tion is what the parents would have done in the absence of
the joint venture.8 8 Therefore, even under this traditional
joint venture analysis, it is possible that companies devel-
oping space pharmaceuticals will not be found in violation
84 Id.
85 Id. at 1608.
86 See United States v. Penn-Olin Chem. Co., 378 U.S. 158 (1964).
87 Pitofsky, supra note 71, at 1608.
88 Id.
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of antitrust laws because, without joint ventures, the firms
probably would never have entered the market at all.
A second concern is that joint venture members will
eventually stifle the joint venture in favor of their own in-
terests. Generally, however, courts are willing to wait un-
til the members of a joint venture actually stifle it to
intercede on this basis.8 9 This reluctance to interfere
arises from common sense considerations based on the
parents' express or implied promise not to compete with
the joint venture and the fact that, realistically, the par-
ents have little incentive to compete with their joint ven-
ture.90 This is of particular relevance in space joint
ventures because the major impetus of the joint venture,
capital risk, will similarly impede any collateral
competition.
A third antitrust concern is the variety of "spill over"
effects from the joint venture that could contribute to di-
minished competition. 9' Since any of these anticompeti-
tive activities would clearly be illegal, the real issue
becomes whether such activities can be inferred from the
mere fact that pharmaceutical companies are involved in
joint ventures or whether actual collusion must be
shown.92 U.S. antitrust law states that proof of collusion
cannot be inferred, even when circumstantial evidence is
available.93 Therefore, the mere existence of a joint ven-
ture, without the existence of other monopoly or illegal
combination activities between the joint venture parties,
will not prove the existence of an "agreement" under sec-
tion one of the Sherman Act. Space joint ventures would,
therefore, only face the same risks as any other U.S. firm.
Outside the normal considerations that would make phar-
89 Id.
90 See Penn-Olin, 378 U.S. at 168.
91 These can include: (1) joint venture partners reaching price fixing agree-
ments; (2) exchange of future price, capacity, or sales volume data; and (3) reduc-
tion of incentives of joint venture partners to compete. Pitofsky, supra note 71, at
1610.




maceuticaljoint ventures illegal, U.S. public policy should
support these operations, despite the danger of possible
anticompetitive effects.
Clearly, Japanese and EEC pharmaceutical companies
attempting to break into the space market are free from
the antitrust concerns that hamper U.S. companies. The
Japanese are free to combine their resources in R&D and
production joint ventures, not because their laws so allow,
but because their laws prohibiting such combinations are
never enforced. The EEC firms, on the other hand, can
legally participate in both R&D and production joint ven-
tures, secure from antitrust liability due to detailed EEC
guidelines. U.S. companies are at a competitive disadvan-
tage for two reasons: first, they cannot participate in pro-
duction joint ventures without facing uncertain levels of
antitrust liability and will not be able to do so until the
NCRA is amended; and second, current R&D joint ven-
tures are open to the subjective scrutiny of the courts
under the "rule of reason," robbing U.S. companies of
any security when undertaking these risky and expensive
joint ventures. This perception of risk is keeping many
large U.S. firms from participating in high technology
joint ventures at a time when they are most needed to
keep the United States competitive in the global
marketplace.
III. FDA REGULATORY SCHEME
One major barrier to the development of new
pharmaceuticals in the United States is Food and Drug
Administration (FDA) regulations. 94 Although regula-
tions are clearly needed to protect the consumer, the
94 21 C.F.R. §§ 1.1-1316.99 (1992). The U.S. food and drug laws are designed
to protect the public by ensuring the purity, efficacy, and safety of drugs on the
market. In formulating food and drug laws, however, the government has never
addressed the issue of space production of pharmaceuticals and thus has never
statutorily indicated the FDA's regulatory jurisdiction in this area. Therefore, an
issue remains whether any FDA jurisdiction conflicts with that of other federal
agencies, such as NASA, which currently has regulatory jurisdiction over civilian
space activities in the U.S. Goodrich, supra note 1, at 238.
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complexity of FDA regulations makes the United States
the world's most difficult country in which to obtain mar-
ket approval for new pharmaceuticals.9 5 Studies suggest
that in the United States it takes an average of twelve
years and $200 million in R&D to develop each new prod-
uct.96 This delay occurs in part because the FDA's review
of new pharmaceuticals is twice as long as that conducted
in most foreign countries. For the space pharmaceutical
industry, concerns arise not only because of the complex
regulatory environment in which pharmaceutical compa-
nies must operate, but also because of the simple fact that
the drafters of current FDA regulations never envisioned
the production of pharmaceuticals in space. Conse-
quently, three major FDA regulatory requirements pose
significant barriers to space pharmaceutical production,
specifically, FDA regulations governing: (1) the enforce-
ment of Good Manufacturing Practices (GMPs); (2) the in-
spection of pharmaceutical production facilities; and
(3) investigational studies and pre-market clearance
procedures.
The FDA's power to regulate pharmaceuticals arises
under the Food, Drug, and Cosmetic Act (FDCA),98 which
mandates that the FDA protect the American public by
ensuring the purity, effectiveness, and safety of
pharmaceuticals in the marketplace. 99 The FDA is not,
however, directed to facilitate the development of new
pharmaceuticals, regardless of their value to consum-
ers.'00 Consequently, the FDA's mandate, directly con-




98 21 U.S.C. §§ 301-394 (1988).
" Id. The Food Drug and Cosmetic Act (FDCA) imposes the highest standard
of care. United States v. Park, 421 U.S. 658, 672 (1975). The FDCA's objective is
to prevent the use of the facilities of interstate commerce to convey impure or
adulterated medicines or foods. McDermott v. Wisconsin, 228 U.S. 115, 128-29
(1913). In so doing, the FDCA was designed to protect not the merchants but
rather the consuming public. United States v. Two Bags, Poppy Seeds, 147 F.2d
123, 127 (6th Cir. 1945).
"-0 Henry G. Grabowski, The Impact of Regulation on Innovation, 34 FOOD DRUG
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flicting with any notion that space pharmaceutical
operations might be afforded special consideration when
subjected to FDA regulations, requires that such opera-
tions strictly comply with all current regulations.
A. GOOD MANUFACTURING PROCEDURES (GMPs)
Complying with current GMPs is the initial regulatory
hurdle for space-produced pharmaceuticals. Such GMPs
are periodically promulgated by the FDA'0 ' and include
extensive guidelines setting out minimum standards for
all phases of pharmaceutical production, including the de-
sign and construction of production facilities, production
and processing controls, and distribution procedures.0 2
These guidelines while adequate to meet the require-
ments of earth-based pharmaceutical production opera-
tions, are totally inadequate for regulating space
production facilities because they do not contemplate the
requirements of either closed-system manned production
facilities or unmanned facilities. 10 3  Additionally, a
number of potential problems threatening the purity and
effectiveness of space-produced pharmaceuticals are not
addressed in the FDA's latest GMPs guidelines. One ma-
jor problem is the unknown affect of cosmic radiation on
space-produced biological products. 0 4 A threat exists
that the concentration and purity of such biological prod-
ucts will be unreliable or that such products might suffer
from dangerous radiation levels. Biological experiments
designed to study such exposure to cosmic radiation have
been conducted aboard the joint Apollo-Soyuz Test Pro-
COSM. L.J. 555, 558 (1979). "There is no corresponding mandate dealing with
drug innovation, or, in particular, with the importance to society of obtaining im-
proved medical therapies." Id.
101 See, e.g., 21 C.F.R. §§ 210.1-211.208 (1992).
102 Id.
103 Some possible problem areas include the FDA requirements for adequate
ventilation, air filtration, heating and cooling, and sewage and refuse disposal. 21
C.F.R. §§ 211.46, 211.48-.50 (1992).
104 See KENNETH W. GATLAND, THE ILLUSTRATED ENCYCLOPEDIA OF SPACE TECH-
NOLOGY 221 (1981).
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ject with inconclusive results. 1 5 Until current GMPs can
be successfully modified to address such space-specific is-
sues, the FDA is statutorily required, as the watch dog of
purity and effectiveness, to keep space-produced
pharmaceuticals off the market, effectively barring the de-
velopment of the U.S. space pharmaceutical industry.
B. INSPECTION OF PHARMACEUTICAL PRODUCTION
FACILITIES
One of the most obvious problems in applying current
FDA regulations to space pharmaceutical production is
the requirement that all pharmaceutical production facili-
ties be inspected by FDA employees every two years. 0 6
This type of inspection clearly will be impossible for the
FDA to conduct, assuming that the actual production fa-
cilities are kept in orbit on a more or less permanent basis
and that only the finished products are returned to earth
periodically. Any failure by the FDA to conduct these in-
spections, however, will inhibit its ability to confirm com-
pliance with GMPs. Since the FDCA defines adulterated
drugs as those that are not produced in accordance with
GMPs,10 7 the inability of the FDA to adequately confirm
GMPs compliance in space production facilities requires
otherwise marketable pharmaceuticals that are produced
at an uninspected space production facility to be automat-
ically branded as adulterated.108 A simple modification of
this requirement, either allowing self-inspection, waiving
inspection upon compliance with certain FDA-mandated
105 Id.
106 21 U.S.C. § 360(h) (1988). The requirement mandates that inspections be
conducted by FDA employees, eliminating the possibility that companies could
conduct self-compliance inspections. Id.
107 Id. § 351(a). Failure to comply with GMP is a violation of the statute, and
the government has no burden to show that the drug in question was actually
deficient as a result of non-conformance with GMPs. United States v. Western
Serum Co., 498 F. Supp. 863, 867 (D. Ariz. 1980).
101 "[F]ailure to follow current GMPs means that the finished product is
adulterated and in violation of the Act even though the finished dosage form is, in
every respect, all it is supposed to be." Patrick Gibbons, Legal Implications of Good
Manufacturing Practice Regulations, 31 FOOD DRUG CosM. L.J. 473, 475 (1976).
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pre-launch inspections, or allowing remote monitoring
through the use of sensing devices aboard the space facil-
ity, would remove this unnecessary barrier while assuring
the quality and purity of space pharmaceuticals.
C. INVESTIGATIONAL STUDIES AND PRE-MARKET
CLEARANCE
The FDCA gives the FDA the responsibility of con-
ducting investigational studies on "new drugs" and pro-
viding pre-market clearance. A "new drug" is defined as
"any drug ... the composition of which is such that such
drug is not generally recognized among experts . . . as
safe and effective for use under the conditions pre-
scribed." 0 9 The FDA, pursuant to its statutory authority,
has promulgated regulations governing applications for
pre-market approval of new drugs." t0 Although an appli-
cant for marketing approval can apply for a waiver of the
application process,"' the FDA is unlikely to approve
such waivers for space-produced pharmaceuticals. Waiver
is unlikely because space-produced pharmaceuticals will
differ in purity and strength from the same chemical com-
pounds produced on earth. Because of these differences,
space-produced pharmaceuticals will generally fall under
the definition of "new drug" and, therefore, be subject to
full investigational screening and the pre-market approval
processes.
- 21 U.S.C. § 321(p)(1) (1988). Additionally, the statute contains a proviso
that "new drugs" also include: "Any drug [determined effective under an investi-
gation outlined in subsection one] but which has not.. . been used to a material
extent or for a material time under such conditions." Id. § 3 2 1(p)(2 ). Space-pro-
duced drugs, although often the same chemical compound as existing earth-pro-
duced drugs, will have greatly increased purity, and their effect on the human
body will be undetermined, consequently making them "new drugs." See also
United States v. Undetermined Quantities of Various Articles of Drug, 675 F.2d
994, 1001 (8th Cir. 1982) (only general recognition plus material use can exempt
a drug from FDA pre-market testing); Farquhar v. Food & Drug Admin., 616 F.
Supp. 190, 192 (D.D.C. 1985) (finding that where neither the individual chemical
ingredient nor the combination of ingredients has been marketed for the uses for
which the producer proposes, it is a new drug).
10 21 C.F.R. 99 314.1-.445 (1992).
11 Id. § 314.90.
1992] 535
536 JOURNAL OF AIR LA WAND COMMERCE [58
Section 355 of Title 21 of the United States Code states
that "[n]o person shall introduce or deliver for introduc-
tion into interstate commerce any new drug unless an ap-
proval ... is effective with respect to such drug." ' 1 2 An
application for such approval requires submitting samples
of the drug under consideration to the FDA.' '3 Presuma-
bly, this sample submission requirement will apply to
space pharmaceuticals even though, at least for a majority
of space pharmaceuticals, there will already be an earth-
produced version on the U.S. market. This requires,
therefore, that pharmaceutical companies begin at least
limited space production prior to knowing whether the
FDA will approve the space version of the pharmaceutical.
Although this risk, necessarily inherent to the protection
of the public, may be acceptable for earth-produced
pharmaceuticals, the capital required for even limited
space production may pose unacceptable investment
risks. This will be especially true in the absence of any
significant antitrust protection for pharmaceutical joint
ventures that would allow companies to spread the invest-
ment risk.' 14
IV. ENVIRONMENTAL CONSIDERATIONS
Although the production of most conventional
pharmaceuticals, whether in space or on earth, poses little
danger to humans or the environment, microbiological
research and production, which is likely to be an integral
part of the space pharmaceutical industry, is considered
112 21 U.S.C. § 355(a) (1988).
-' Id. § 355(b).
114 In a similar vein, § 355(c) gives the FDA 180 days in which to approve the
application or offer the applicant the opportunity to have a hearing on the applica-
tion. Id. § 355(c). This time-table may be unacceptable because of the massive
investment that pharmaceutical companies make in their space production facili-
ties. Allowing such large amounts of capital to be tied up in idle facilities during
the approval process may drive the rate of return on such capital investments
down to a point where the investment becomes unacceptable to both managers
and shareholders. This issue may be avoided, however, if the FDA is liberal in
allowing exceptions to permit the commencement of pre-clinical testing while the
application is under consideration.
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an ultrahazardous undertaking." l5  Microbiological re-
search involves the use of genetic engineering, recombi-
nant DNA, and bacteria to produce drugs and
antibodies." 6 Because of their invasive properties, un-
known behavior in space, and ability to reproduce, micro-
biological organisms pose significant environmental
dangers in the event of an accidental release.' 1 7 Although
performing microbiological experiments in space pro-
vides some measure of safety to the earth's environment,
risks still exist. The most direct danger is the possibility
of a crash of the microbiological payload, either on launch
or out of a disintegrating orbit. Other risks are posed by
either release on the moon or other space body, or by an
accidental release into space. Although these alternative
releases pose much less danger, it is possible that some
microbiological organisms could survive the conditions of
space and contaminate the Earth upon capture by the
115 See William Klien, U.S. Biological Experiments in Space, 8 ACTA ASTRONAUTICA
927 (1981).
116 See OFFICE OF TECHNOLOGY ASSESSMENT, PUB. No. OTA-HR-132, IMPACTS
OF APPLIED GENETICS: MICRO-ORGANISMS, PLANTS AND ANIMALS (1981).
"17 Even in the presence of adequate containment facilities and good decontam-
ination equipment, the success of attempts to control microbiological contamina-
tion depends in part on the work techniques of the involved personnel. Although
no inclusive list of correct techniques would be appropriate for all areas of appli-
cation of microbiological contamination control, some fundamental notions are
listed below:
a. Microbial contamination can exist and yet not be readily detecta-
ble in the usual sense.
b. The contamination may be odorless, tasteless, and invisible.
c. Instantaneous monitoring devices for microorganisms, compara-
ble to devices for detecting radioactive contaminants, are not
available.
d. It is important to understand the ease with which microorga-
nisms can be made airborne and their ability to remain airborne
in small particle form and to move from place to place in air
currents.
e. It is significant that the physical state of a microbiological con-
taminant is related to the ease or difficulty of containment.
Dried, micronized, powdered, or lyophilized microbial prepara-
tions are much more difficult to contain than contaminates in a
wet or fluid state.
N68-31008 NASA-CR-92209 Comprehensive Biological Protocol For the Lunar
Sample Receiving Laboratory, June 16, 1967, (on file with Baylor Univ. College of
Medicine).
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earth's gravity." 8 Consequently, space research and pro-
duction involving microbiological pharmaceuticals raises
serious environmental issues.
To deal with these types of environmental hazards,
Congress passed the National Environmental Policy Act
(NEPA).t1 9 The FDA recognizes that it has substantial re-
sponsibilities under NEPA t20 and therefore mandates that
environmental impact consideration be an integral part of
its regulatory processes, including the approval of New
Drug Applications (NDA).1 21 Under current regulations,
unless a waiver is obtained, an Environmental Assessment
Statement (EAS) must be prepared for every NDA in ac-
cordance with NEPA review procedures 22 and Depart-
ment of Health and Human Services guidelines. 2 3 As a
federal agency, the National Aeronautics and Space Ad-
ministration (NASA) is also subject to NEPA require-
ments 24 and must prepare either Environmental Impact
Statements (EIS) or an EAS for any NASA actions having
a potentially significant impact on the environment.
25
Although NEPA is limited to the territorial boundaries
118 MARTIN WERBER, OBJECTIVES AND MODELS OF THE PLANETARY QUARANTINE
PROGRAM NASA SP-344 (1975).
1,9 42 U.S.C. §§ 4321-4370c (1988).
120 21 C.F.R. § 25.1 (1992).
121 Id. § 25.22.
122 40 C.F.R. § 1502.01-25, 1508.9 (1992).
123 Environmental Assessments are prepared following the guidelines of 21
C.F.R. §§ 25.30-.34 and reviewed by the FDA under the procedures in §§ 25.40-
.42.
124 42 U.S.C. § 4332(c) (1988).
125 NASA regulations state that either an EAS or an EIS is required when
"NASA actions [are] expected to have a significant effect on ... the... environ-
ment." 14 C.F.R. § 1216.305(c) (1992). The choice between an EAS or an EIS is
dependent upon the perceived risk of the project under consideration. NASA
regulations state that an EAS will be required when "specific spacecraft develop-
ment and flight projects in space ... [and] reimbursable launches of non-NASA
spacecraft or payloads ... lead, either directly or indirectly, to natural or physical
environmental risks." Id. § 1216.305(b). An EIS, on the other hand, is required
when the "development and operation of space vehicles [is] likely to release sub-
stantial amounts of foreign materials into the Earth's atmosphere or into space."
Id. § 1216.305(c). Since most space launches, even commercial ones, will likely
involve substantial NASA participation, these regulations will impose the burden
of preparing either an EAS or an EIS before all launches. Id.
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of the United States, consideration of potential extraterri-
torial impacts is required. 26 Other countries, therefore,
may have a role to play in determining the potential envi-
ronmental effect of any space launch bearing a potentially
environmentally dangerous payload 27 since it is arguable
that the public participation provision in NEPA 128 would
allow foreign party participation in pre-launch environ-
mental impact assessments.' 29 This involvement would
provide an instrument for foreign lobby groups in Wash-
ington to exert pressure in an attempt to undermine any
commercial utilization of space by U.S. pharmaceutical
companies.
Because of the potential impact on the environment,
the scope of environmental impact assessments regarding
microbiological research and production in space goes
beyond anything previously encountered by pharmaceuti-
cal producers and represents an additional financial and
regulatory burden. However, because of the launch and
recovery risks and the risks of keeping microbiological re-
search and production materials in space for extended pe-
riods of time, the added costs placed on the industry to
produce an EAS or EIS are warranted when weighed
against the potentially devastating results of a serious mi-
crobiological accident. The system must not, however,
become a forum for foreign interest groups to hinder U.S.
space pharmaceutical development.
V. PATENTS IN MEDICINE
The intellectual property of private industry is vital to
its existence. The information and technology that make
126 Id. § 1216.321 (1992). These include potential effects on the global com-
mons (i.e., oceans and the upper atmosphere) and on foreign nations neither par-
ticipating with nor otherwise involved in the NASA activity. Id.
127 Philip McGarrigle, Hazardous Biological Activities in Outer Space, 18 AKRON L.
REv. 103, 123 (1984).
128 14 C.F.R. § 1216.309 (1992); see Wilderness Soc'y v. Morton, 463 F.2d 1261
(D.C. Cir. 1972), Saipan v. Department of the Interior, 356 F. Supp. 645 (D. Haw.
1973), modified, 502 F.2d 90 (9th Cir. 1974).
129 McGarrigle, supra note 127, at 124.
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up the proprietary data and trade secrets of a private in-
dustry are the lifeblood of that industry. To the extent
that the right to retain and protect such technology is di-
luted or lost, the industry will be weakened or destroyed.
Thus, a vital issue of security for private industry in its
outer space activities is its ability to maintain its proprie-
tary position. 130
The United States utilizes a first-to-invent patent sys-
tem, under which patents are granted to the first party to
prove invention of a particular item.' 3 ' In contrast, the
patent systems used in both Japan and Europe are first-to-
file systems, where the first-to-invent is immaterial with
regard to patent rights, since the rights hinge merely on
who files a patent application first. 32 This difference may
have a serious impact on U.S. pharmaceutical companies'
efforts to protect new pharmaceuticals developed in
space, thereby inhibiting the industry's development.
Generally, U.S. pharmaceutical companies have to
choose between statutory patent protection or non-statu-
tory trade secret protection to protect new products. By
choosing to file for patent protection under the U.S. first-
to-invent system, pharmaceutical companies, although
gaining protection in the U.S. market, are vulnerable to
European and Japanese pharmaceutical companies who
may win the race to the patent office in first-to-file coun-
tries. This risk serves as a major deterrent to U.S. firms'
willingness to engage in R&D because their return on in-
vestment is subject to higher risk. However, absent a spe-
cial ability by European or Japanese firms to win the race
to the patent office in their respective countries, U.S.
pharmaceutical companies will be able to "steal" their
share of the patent rights to new products. Unfortunately
this type of competition, which increases investment risks,
favors Japanese and European firms that are better able to
130 Roger K. Hoover, Law and Security in Outer Space From the Viewpoint of Private
Industry, llJ. SPACE L. 115, 122 (1983).
I3 ANDREWJ. YOUNG, LAW AND POLICY IN THE SPACE STATIONS' ERA 171 (1989).
132 Gerald J. Mossinghoff, Intellectual Property Rights in Space Ventures, 10J. SPACE
L. 107, 110 (1982).
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spread the investment risk among joint venture
partners.t 3
In addition to problems raised by the first-to-file coun-
tries, the U.S. patent system provides a number of ob-
structions to the patenting of medical technology, all of
which will adversely effect the space pharmaceutical in-
dustry. These have generally arisen because of the clash
between the fundamental nature of medical technology
and the operating framework of the U.S. Patent Office. 3 4
To obtain a U.S. patent, the applicant must prepare a pat-
ent application describing at least one embodiment of the
invention in sufficient detail to enable any person skilled
in the art to make and use the invention.3 5 The patent is
then examined by the Patent Office and rejected if it is
either anticipated by prior art 36 or obvious. 3 7  Since
medical inventions are by their nature different than
mechanical inventions, different types of patent practices
have evolved that often deny patents to medical inven-
tors 38 and, even when issued, offer little real protection
to the patent holder since current practice tends to re-
strict the scope of medical patents, making them difficult
to defend. Additionally, lengthy FDA investigatory and
pre-market clearance procedures consistently reduce the
useful life of medical patents. Finally, much of the devel-
oping world refuses to acknowledge medical patents and
M See supra notes 25-49 and accompanying text.
134 William D. Noonan, Patenting Medical Technology, 11 J. LEGAL MED. 263, 263
(1990).
The Patent Office was founded in the 18th century and evolved dur-
ing an age of progress in mechanical engineering. Many of the basic
doctrines of patent law ... reflect a bias toward the mechanical tech-
nology that patent law was designed to protect [therefore] patent
law has repeatedly been modified in haphazard fashion to deal with
more biologically oriented medical technology. These legal modifi-
cations have riddled the law of medical patents with numerous ex-
ceptions to the already complex rules that govern patents in other
technologies.Id.
I5 35 U.S.C. § 112 (1988).
136 Id. § 102.
137 Id. § 103.
138 Noonan, supra note 134, at 271.
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refuses to afford such patents any protection from in-
fringement, claiming a right to copy such pharmaceuticals
without regard for their patented status. 39
A. PATENTABILITY
The first significant statutory hurdle to obtaining a
medical patent is that a patent application must clearly
state the patented item's intended use, 40 meaning the
utility of new pharmaceuticals must be clearly stated and
often proved before a patent will be issued.' 4' Although a
logical requirement, such proof is often difficult to pro-
vide except in the most abstract sense. The Patent Office,
therefore, has developed a practice of presuming the util-
ity of mechanical devices, making those patent applica-
tions more cost effective and less rigorous to obtain than
the statutory requirements would indicate. The same is
not true, however, for medical patents, making such pat-
ents extremely difficult to obtain. 42 Because all pharma-
ceutical companies within the U.S. market are subject to
the same increased costs and risks, this disparity of treat-
ment may seem immaterial; however, this problem has an
overall impact on the ability of U.S. firms to compete in
the world market. U.S. companies, instead of seeking
U.S. patent protection, may rely on non-statutory trade
secret protection. This makes their new products vulnera-
ble to copying through reverse engineering activities re-
sulting in competitors quickly bringing competing
products into the U.S. marketplace. This entrance is sig-
nificant because the United States is one of the world's
largest pharmaceutical markets and is currently a primary
source of revenues for U.S. pharmaceutical companies.
Like the Japanese and the Europeans, U.S. pharmaceuti-
cal companies depend largely on controlling their home
markets to provide capital to finance global selling opera-
139 Id.
140 35 U.S.C. § 112 (1988).
141 Noonan, supra note 134, at 276.
142 Id.
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tions. Once control of this home market is lost or
threatened, U.S. firms may not have the capital needed to
compete in the global space pharmaceutical market.
In addition to the utility requirement, U.S. patent law
raises several other potential barriers that will have a
unique effect on the space pharmaceutical industry.
These include the statutory requirements of novelty,1
43
mandating that patents not be granted on existing phar-
maceutical compounds, 44 and non-obviousness.145 The
majority of pharmaceuticals produced in space will merely
represent increases in purity and strength over
pharmaceuticals currently produced on earth. Whether
companies will be able to obtain patent protection on
such modified compounds, in light of the novelty and
non-obviousness requirements, is questionable. Case law
indicates, however, that increased purification will qualify
them as patentable inventions 46 and that pharmaceutical
companies will be allowed some flexibility in this area, es-




Once a medical patent is obtained it must, of course, be
defended against infringement. Typically, defending a
medical patent is difficult because heightened require-
ments for medical patent enablement and proof of utility
result in a patent whose scope is so narrow as to be virtu-
ally useless. This happens because any chemical's activity
is subject to a great deal of unpredictability. The Patent
Office, therefore, requires that pharmaceutical patents be
limited in scope to those chemical effects that can be de-
143 35 U.S.C. § 102 (1988).
144 See Noonan, supra note 134, at 281.
1-5 35 U.S.C. § 103 (1988).
146 See Merck & Co. v. Orlin Mathieson Chem. Corp., 253 F.2d 156, 163 (4th
Cir. 1958) (finding that the fact that a new and useful product results from
processes of extraction, concentration, and purification of natural materials does
not defeat its patentability).
141 See Noonan, supra note 134, at 287.
54319921
544 JOURNAL OF AIR LA WAND COMMERCE [58
scribed and proven. 48 This differs from mechanical pat-
ents that are routinely accorded a broad scope of
protection. 49 Pharmaceutical companies will, therefore,
receive less patent protection on their products, 50 result-
ing in increased difficulty and expense to protect medical
patents from infringement simply because chemical prin-
ciples are not afforded a substantial scope of protection.
C. PATENT LIFE
U.S. patents are granted for seventeen years giving the
holder a legal monopoly on a given product as a reward
for innovation. Historically, however, pharmaceutical pat-
ents have a much shorter practical life, making recoup-
ment of the massive investment required to develop
patented pharmaceuticals difficult.' 5 ' This shortened
practical life occurs because medical patents are generally
obtained prior to marketing and subsequent periods of
148 Id. at 273.
149 Id.
5o Id. at 274.
15, During the period 1960-1980 the effective life of pharmaceutical patents de-
creased from 16 years to less than 10 years because of the increased time required
for FDA review. New Life of Patents, 24 AM. FAM. PHYSICIAN 90 (1981).
Although no hard data exists on the costs of developing space pharmaceuticals,
all projections point to increased costs over earth-produced pharmaceuticals.
Government studies show that the average cost of bringing a new chemical entity
to market is approximately $33 million (1976 dollars). OFFICE OF TECHNOLOGY
ASSESSMENT, PATENT-TERM EXTENSION AND THE PHARMACEUTICAL INDUSTRY 13
(1981).
Additionally, new pharmaceuticals have fairly standard development lives that
include the following stages: (1) Discovery Stage, involving the isolation of the
new drug; (2) Preclinical Stage, involving initial toxicity testing on animals; (3)
Patent Application Process, that might begin as early as the Discovery Stage; (4)
Safety and Efficacy Testing Stage, involving clinical testing and long-term toxicity
testing; (5) Patent Examination and Grant Phase, generally occurring at the same
time as the Safety and Efficiency Testing Stage; (6) NDA Stage, during which the
NDA is submitted and approved by the FDA; and (7) Marketing Stage, during
which the pharmaceutical is sold to the public. Id. at 12-15.
The major time delays occur in the NDA stage which, in the 1980s, could last as
long as seven years while the FDA conducted safety and efficacy tests. Addition-
ally, the NDA is only approved by the FDA for its stated process and therapy. Any
changes in the composition of the pharmaceutical or new uses require a supple-
mental NDA and new FDA approval. Therefore, by the time the new pharmaceu-
tical makes it to the market, a substantial portion of the patent term is lost. Id.
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mandatory federal pre-marketing and pre-manufacturing
regulation reduce effective patent lives.'1 2
Concerned that decline in the average effective life of
pharmaceutical patents would diminish profits, thereby
decreasing the funds available for research and develop-
ment and ultimately the number of new pharmaceuticals
introduced in the United States, 5 3 Congress passed the
Drug Price Competition and Patent Term Restoration Act
of 1984.15 4 The Patent Term Restoration Act extends the
period of pharmaceutical patent protection to compen-
sate for periods of FDA review.' 55 Generally, the patent
term is now extendable to include the time the drug was
under FDA review as a New Drug Application (NDA) and
one-half the time during which the drug was in clinical
testing as an Investigational New Drug (IND). 56 The Pat-
ent Term Restoration Act will have a significant facilitat-
ing effect on the space pharmaceutical industry and
represents part of a growing trend in Congress to boost
the competitiveness of U.S. pharmaceutical companies in
the global market.
D. DEVELOPING NATIONS
One of the most difficult issues in international trade
relations is the protection of intellectual property. Many
developing countries reject developed countries' claims
for intellectual property protection in areas such as
pharmaceuticals, which the developing countries see as vi-
152 OFFICE OF TECHNOLOGY ASSESSMENT, PATENT-TERM EXTENSION AND THE
PHARMACEUTICAL INDUSTRY 13 (1981).
15 Id.
- 35 U.S.C. §§ 155-156 (1988).
155 Id. The Patent Term Restoration Act allows patent extension if: (1) the pat-
ent term has not already expired; (2) no previous extension has been granted; (3)
the extension application was filed within 60 days of the pharmaceutical's NDA
being approved; (4) the drug was subject to a regulatory review prior to commer-
cial marketing; and (5) the commercial marketing was the first allowed by the reg-
ulatory statute. Id. See also 37 C.F.R. § 1.750 (1992). Interim extensions of up to
one year are available while § 1.750 extensions are pending. Id. § 1.760.
1- 37 C.F.R. § 1.775 (1992).
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tal to their national well-being. 157 These countries often
have national policies and laws that encourage the "steal-
ing" of pharmaceutical inventions.' 5" Regardless of any
arguments justifying or condemning such practices, these
"pirated" pharmaceuticals adversely affect the pharma-
ceutical industry in the United States and other developed
countries by significantly reducing return on their invest-
ments in pharmaceutical development.' 5 9 Although these
"pirated" pharmaceuticals will not directly compete with
space-produced pharmaceuticals, they pose two threats to
industry development. First, they reduce the overall finan-
cial health of companies thereby reducing the capital
available for space research and development. Second, as
the commercial use of space becomes increasingly avail-
able to developing countries, they may be able to develop
their own space pharmaceutical programs, again raising
the specter of "pirated" pharmaceuticals. Until the Gen-
eral Agreement on Tariffs and Trade (GATT) addresses
such issues, two consequences are likely to develop.
Either the space pharmaceutical industry's growth will be
retarded altogether or such products will not be offered
to developing countries until they offer meaningful pro-
tection, thereby excluding those countries from the bene-
fits of industry development.
VI. INTERNATIONAL SPACE TREATIES
International space treaties to which the U.S. is a signa-
tory affect all commercial uses of space, including the de-
velopment of space pharmaceuticals. 160  The principle
1.1 The major developing countries providing no protection for pharmaceutical
property rights are Brazil, China, India, Argentina, Chile, Mexico, Thailand, and
the countries of Eastern Europe. Drug Trade Seeks Leverage on Patents, CHEMICAL
MARKETING REP., Oct. 29, 1990, at 5.
158 Id.
159 Patent infringement in Brazil, for example, is estimated to cost the industry
$100 million a year. Industrial Property Bill Suffers Setback in Brazilian Congress, INT'L
Bus. DAILY (BNA), July 24, 1991.
- See Treaty on Principles Governing Activities of States in the Exploitation
and Use of Outer Space, Including the Moon and Other Celestial Bodies, Jan. 27,
1967, 18 U.S.T. 2410, 610 U.N.T.S. 205 (effective Oct. 10, 1967) [hereinafter
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agreement concerning the commercial use of space' 6 1 was
prompted by the many anticipated international problems
created by increased activities in space and the upper at-
mosphere. 62 Its principal purpose is ensuring that "[t]he
exploration and use of outer space ... be carried out for
the benefit ... of all countries.' 63
Developing countries are attempting to use the Space
Treaty's broad purposes as justification for demanding ac-
cess to scientific information gathered by developed na-
tions' space programs. They argue that, under the Space
Treaty, ratifying nations with space programs, either gov-
ernmental or private, have an obligation to disclose scien-
tific discoveries.' 64 This contention is grounded in the
language of article XI of the Space Treaty, which calls for
Space Treaty]; The Agreement on the Rescue of Astronauts, the Return of Astro-
nauts and the Return of Objects Launched into Outer Space, Apr. 22, 1968, 19
U.S.T. 7570, 672 U.N.T.S. 119 (effective Dec. 3, 1968).
161 Space Treaty, supra note 160. Initially the United States and the Soviet
Union advocated differing principles for the Space Treaty. In an unsuccessful at-
tempt to inhibit the development of an American commercial space industry the
Soviet version, which was never adopted, allowed only for governmental space
programs stating that "[a]ll activities of any kind pertaining to the exploration or
use of outer space shall be carried out solely and exclusively by States." U.N.
Doc. A/AC.105.C.2/L.I, at 3 (1962).
162 JOSEPH G. STARKE, INTRODUCTION TO INTERNATIONAL LAw 171 (9th ed.
1984). These activities include not only manned and unmanned space launches
but also research on the nature of space, cosmic radiation, radiation zones around
the earth, magnetic fields surrounding the earth, the ionosphere, and micro-mete-
orite density. Id.
163 Space Treaty, supra note 160, at art. I. Article I states:
The exploration and use of outer space, including the moon and
other celestial bodies, shall be carried out for the benefit and in the
interests of all countries, irrespective of their degree of economic or
scientific development, and shall be the province of all mankind.
Outer space, including the moon and other celestial bodies, shall be
free for exploration and use by all states without discrimination of
any kind, on the basis of equality and in accordance with interna-
tional law, and there shall be free access to all areas of celestial bod-
ies. There shall be freedom of scientific investigation in outer space,
including the moon and other celestial bodies, and States shall facili-
tate international co-operation in such investigation.
Id.
A See Stephen Gorove, The 1980 Session of the U.N. Committee on the Peaceful Uses
of Outer Space: Highlights of Positions on Outstanding Legal Issues, 8J. SPACE L. 174, 187
(1980).
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the results of all scientific activities to be disclosed to the
international community to the greatest extent feasible. 6 5
Any such disclosure required by private industry or the
Patent Office before granting of a patent, however, would
seem to run counter to the intent of Title 35, section 105
of the United States Code, which purports to extend U.S.
patent law to outer space. To establish the effect of article
XI on U.S. patent law, therefore, requires determining
whether the Space Treaty is a self-executing treaty and, if
so, whether it has been abrogated by subsequent congres-
sional legislation.
Normally the passage of the Space Patent Act' 6 6 by
Congress, extending U.S. patent protection to outer
space, would make the question of whether the Space
Treaty mandates pre-patent disclosure of patentable in-
ventions a moot issue, since the later patent law would
generally abrogate any disclosure requirement of the ear-
lier Space Treaty.16 7  The Space Patent Act, however,
leaves open the possibility that it does not always apply to
space objects when they are "otherwise provided for by
an international agreement to which the United States is a
party."'1 68 Since it is arguable that this language refutes
any clear congressional intent to supersede the Space
Treaty, it is necessary to determine whether the Space
Treaty ever became effective U.S. law, and if so, whether
165 Space Treaty, supra note 160, at art. XI. Article XI of the Space Treaty
states:
In order to promote international co-operation in the peaceful ex-
ploration and use of outer space, States Parties to the Treaty con-
ducting activities in outer space, including the Moon and other
celestial bodies, agree to inform the Secretary-General of the United
Nations as well as the public and the international scientific commu-
nity, to the greatest extent feasible and practicable, of the nature,
conduct, locations and results of such activities. On receiving the
said information, the Secretary-General of the United Nations
should be prepared to disseminate it immediately and effectively.
Id.
166 35 U.S.C. § 105 (Supp. 1991).
167 See United States v. Palestine Liberation Org., 695 F. Supp. 1456, 1464
(S.D.N.Y. 1988).
- 35 U.S.C. § 105 (Supp. 1991).
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the Space Patent Act was intended by Congress to super-
sede any mandatory pre-patent disclosure requirement
that can be read into the Space Treaty.
The first issue is whether the Space Treaty ever became
effective U.S. law. Once signed and ratified, a self-execut-
ing treaty becomes the supreme law of the land;' 69 how-
ever, when a treaty is too broad or vaguely-worded to
effectively stand alone, it requires implementing legisla-
tion.1 70 Those who argue that the Space Treaty became
U.S. law in the absence of any extraterritorial application
of U.S. patent law are, therefore, in a "Catch-22" situa-
tion. The plain language of article I of the Space Treaty
articulates two primary concerns: the "free right of ac-
cess" to space17' and "freedom of scientific investigation"
of space.' 72 Therefore, any narrow reading of the Treaty
to avoid the need for implementing legislation would not
reasonably allow the inference of a mandatory pre-patent
full disclosure requirement, since article XI of the Treaty
only requires discretionary disclosure to the "greatest ex-
tent feasible and practicable."'' 7 3 On the other hand, a
broad reading requiring mandatory pre-patent full disclo-
sure to the international community results in a treaty
clearly not specific enough to become law without imple-
menting legislation because it does not "establish affirma-
tive and judicially enforceable obligations." 74
I- U.S. CONST., art. VI, cl. 2.
170 See Saipan v. Department of the Interior, 502 F.2d 90, 97 (9th Cir. 1974).
The extent to which an international agreement establishes affirma-
tive and judicially enforceable obligations without implementing leg-
islation must be determined in each case by reference to many
contextual factors: the purposes of the treaty and the objectives of
its creators, the existence of domestic procedures and institutions
appropriate for direct implementation, the availability and feasibility
of alternative enforcement methods, and the immediate and long-
range social consequences of self- or non-self-execution.
Id.
171 Space Treaty, supra note 160, at art. I, cl. 2.
172 Id. at ci. 3.
,73 Id. at art. XI.
174 Saipan, 502 F.2d at 97; see Chew Heong v. United States, 112 U.S. 536, 554
(1884).
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Additionally, regardless of the need for implementing leg-
islation, any legal challenge to non-disclosure in a U.S.
court will probably lead the court to harmonize the Space
Treaty and existing patent law, but the court will still not
require disclosure. 175
The second issue is whether Congress intended the
Space Patent Act to abrogate any possible disclosure re-
quirements that can be read into the Space Treaty. In re-
sponse to commercial concerns regarding the
extraterritorial effect of U.S. patent law, the federal gov-
ernment undertook a two-step response to the need for
protection of private commercial space operations. First,
in an attempt to promote the commercial utilization of
space, NASA waived its exclusive property right to inven-
tions created during projects it supports. 176 This waiver
allowed private parties to acquire rights to any inventions
or processes developed in space notwithstanding NASA
involvement. Second, Congress extended patent protec-
tion to processes and inventions created in space.' 77 Prior
175 This type of harmonizing is often done by U.S. courts when conflicts arise
between domestic law and international agreements. In Palestine Liberation Organi-
zation, 695 F. Supp. at 1456, the court harmonized the Agreement Between the
United States and the United Nations Regarding the Headquarters of the United
Nations (the Agreement) and §§ 5201-5203 of Title 22 of the United States Code,
the Anti-Terrorism Act (ATA). The Agreement allowed the Palestine Liberation
Organization (PLO), at the invitation of the United Nations, to "participate in the
sessions and the work of the General Assembly in the capacity of observer," which
necessarily included the right of PLO representatives to enter the United States.
Id. at 1459. The ATA stated that the PLO was a "terrorist organization and a
threat to the interests of the United States... and should not benefit from operat-
ing in the United States." 22 U.S.C. § 5201(b) (1988). The court held the ATA
inapplicable to the Agreement because: (1) the ATA did not specifically mention
the Agreement; (2) the ATA did not purport to apply notwithstanding any treaty;
and (3) there was no clear congressional intent to supersede the Agreement. 695
F. Supp. at 1468-69.
176 42 U.S.C. § 2457(a) (1988). The National Aeronautics and Space Act gave
the United States exclusive rights to any invention developed in connection with
NASA. Id. Over the years, however, NASA implemented policies such as the
Joint Endeavor Agreement to promote commercial investment, and laws have
since limited NASA's claim to exclusive rights. See, e.g., 35 U.S.C. § 200 (1988)
(establishing congressional intent to use the patent system to promote the utiliza-
tion of inventions arising from federally supported research and development).
177 35 U.S.C. § 105 (Supp. 1991).
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to passage of Space Patent Act,' 78  U.S. patent laws would
not have applied to U.S. spacecraft. 79 Because the Space
178 Section 105 states:
(a) Any invention made, used or sold in outer space on a space
object or component thereof under the jurisdiction or control of the
United States shall be considered to be made, used or sold within
the United States for the purpose of this title, except with respect to
any space object or component thereof that is specifically identified
and otherwise provided for by an international agreement to which
the United States is a party, or with respect to any space object or
component thereof that is carried on the registry of a foreign state
in accordance with the Convention on the Registration of Objects
Launched into Outer Space.
(b) Any invention made, used, or sold in outer space on a space
object or component thereof that is carried on the registry of a for-
eign state in accordance with the Convention Registration of Objects
Launched into Outer Space, shall be considered to be made, used,
or sold within the United States for the purposes of this title if spe-
cifically so agreed in a international agreement between the United
States and the state of registry.
ld.
179 All U.S. patent law prior to the enactment of the Space Patent Act extended
United States patent jurisdiction on a territorial basis. Although often thought of
as "territories," ships, embassies, and, in this case, spacecraft are not a nation's
territory for patent purposes. See Cunard S.S. Co. v. Mellon, 262 U.S. 100, 123
(1923) (arguing that "the jurisdiction which [the "floating island" theory] is in-
tended to describe arises out of the nationality of the ship, as established by her
domicile, registry and use of the flag, and partakes more of the characteristics of
personal than territorial sovereignty"). This concept of a ship as national terri-
tory is false. Jurisdiction over a ship or embassy actually arises from the ship's or
embassy's nationality and the rights associated with that nationality under interna-
tional law. Patents in Space Hearings, supra note 8, at 48-49 (statement of Professor
Glenn H. Reynolds, Associate Professor, College of Law, Univ. of Tenn.).
U.S. patent law prior to the Space Patent Act did not provide extraterritorial
protection, since 35 U.S.C. § 100(c) provided that for patent law purposes: "[tihe
terms 'United States' and 'this country' mean the United States of America, its
territories and possessions." 35 U.S.C. § 100(c) (1988). The Supreme Court
held in Deepsouth Packing Co. v. Laitram Corp., 406 U.S. 518 (1972), that the
United States patent system had no extraterritorial effect and was not intended to
apply to activities taking place outside the country's territorial limits. Id. at 531.
See also Lam Mow v. Nagle, 24 F.2d 316, 317-18 (9th Cir. 1928) (holding that a
foreign baby born on a U.S. flagged ship was not born in U.S.); United States v.
12536 Gross Tons of Whale Oil ex rel the Charles Racine, 29 F. Supp. 262, 267
(E.D. Va. 1939) (holding that an American flag ship was not a "point" in the
United States for purposes of statute prohibiting transportation "between points
in the United States"). Cf Gardiner v. Howe, 9 Fd. Cas. 1157, 1158 (C.C.D. Mass.
1856) (No. 5219) ("The patent laws of the United States afford no protection to
inventions beyond or outside of the jurisdiction of the United States; but this ju-
risdiction extends to the decks of American vessels on the high seas, as much as it
does to all the territory of the country .... "). Despite the accumulation of case
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Patent Act rejects the traditional territorial limitation in
favor of a jurisdictional scope identical to that used in the
Space Treaty, U.S. patent law now clearly applies to U.S.
flagged spacecraft. 8 ° Article VIII of the Space Treaty
provides for national jurisdiction over spacecraft under a
State's national registry. Congress borrowed the term
"space object" directly from the Space Treaty for use in
the statute and clearly intended that term to have the
broadest possible meaning.' 8 ' This portion of the patent
laws, therefore, represents a conscious departure from
prior practice, indicating that Congress meant the term to
encompass national jurisdiction as used in the Space
Treaty rather than territorial jurisdiction as previously ap-
plied to U.S. patent law by the Supreme Court. Congres-
sional intent was clearly to protect U.S. entities inventing
in space under the U.S. patent laws and to abrogate any
disclosure requirements that could be read into the Space
law, conflicts still arise. The general counsel of intellectual property at NASA
stated the position that "an object in space is an extension of the launching na-
tion" and, therefore, is protected by U.S. patent law. James Evans, One Giant Leap
for the Space Bar, CAL. LAW., Nov. 1987, at 36, 83. Evans notes, however, that the
Justice Department argued in Hughes Aircraft Co. v. United States, 717 F.2d
1351, 1356-63 (Fed. Cir. 1983), that United States patent law was restricted to
United States territory. Evans, supra note 84.
180 There are several bases for asserting jurisdiction under international law:
(1) The Territorial Principle: The principle comes from the terri-
torial nature of sovereignty which permits courts of the place where
a crime or tort occurred to exercise jurisdiction.
(2) The Nationality Principle: This comes from a state's power to
exercise jurisdiction over its nationals regardless of where they are
located.
(3) The Passive Personality Principle: This principle bases juris-
diction on the nationality of the victim of a crime.
(4) The Protective Principle: This principle bases jurisdiction on
where the act committed abroad has an adverse effect.
(5) The Universality Principle: Here the act committed is so uni-
versally condemned that any nation has jurisdiction.
See Patents in Space Hearings, supra note 8, at 47-48 (statement of Professor Glen H.
Reynolds). See also GLENN H. REYNOLDS & ROBERT P. MERGES, OUTER SPACE:
PROBLEMS OF LAW AND POLICY 248-49 (1989) (outlining the five traditional princi-
ples of jurisdiction in international law).
I'l Patents in Space Hearing, supra note 8, at 24 (testimony of Alan J. Kerczko,
Deputy Legal Advisor, U.S. Dept. of State).
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Treaty. 1 82
VII. CONCLUSION
The development of the space pharmaceutical market
in the post cold war era will be a test of the ability of the
three major industrial blocks, the United States, Japan,
and the EEC, to adapt themselves for global competition
in the next 100 years. To succeed, the U.S. must provide
its major pharmaceutical firms with the same advantages
enjoyed by Japanese and EEC companies. U.S. antitrust
law must be amended to acknowledge the realities of the
global marketplace by allowing production joint ventures
and by removing from the courts the broad powers to im-
pose antitrust liability based on their subjective belief in
what is "reasonable." Without such protection, U.S. firms
will not be able to raise the capital needed to effectively
182 Hearings on the Patents in Space Act made it clear that Congress intended
to fully protect U.S. patent holders from any form of international disclosure re-
quirement by applying the U.S. patent system to outer space. Chairman Kas-
tenmeier stated that the four principle objectives of the bill were: (1) providing
that actions occurring in outer space can infringe on United States' patent law; (2)
assuring that the United States "first-to-invent" system was extended to space in-
ventions; (3) regulating "prior art"; and (4) protecting security by insuring that
space inventions are governed by the Invintion Security Act. Id. at 1 (statement
of Rep. Robert W. Kostenmeier, Subcommittee Chairman). Additionally, testi-
mony before the subcommittee indicated that the Act was designed to provide
certainty for entities conducting space operations and to avoid any uncertainty
that might arise if the right of an entity to a patented invention or idea was sub-
jected to case-by-case judicial scrutiny. James E. Denny of the United States Pat-
ent and Trademark Office stated that:
Relegating [the issue of patent protection of space inventions] to
time-consuming judicial interpretation would subject the industry to
expensive litigation with case-by-case determinations based on indi-
vidual fact situations. The time and expense required to obtain legal
certainty under these circumstances pose potential dis-incentives to
research and development in outer space. And because the result of
such litigation cannot be assured, our industry deserves the certainty
that can be provided by legislation.
Id at 16 (statement ofJames E. Denny, Acting Assistant Comm'r for Patents, U.S.
Patent and Trademark Office).
Clearly, one purpose of this legislation was to remove any possibility of judicial
interpretation of the applicability of U.S. patent protection in light of the Space
Treaty and any purported disclosure requirements.
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utilize space as a production facility and will be unable to
spread R&D risk.
FDA regulations also need to be revised to create a reg-
ulatory environment that is conducive to space develop-
ment but that still fulfills the essential role of the FDA in
protecting the American public. This rule should include
ensuring environmental protection from the dangers of
contamination by microbiological organisms. Because of
the potentially devastating effect of a microbiological acci-
dent, environmental protection should be an issue in
which few compromises are made in favor of industry de-
velopment. It is also incumbent on the United States gov-
ernment to press for an international standard of safety
and environmental review to prevent accidents by other
nations and to ensure that other nations' industries are
subject to the same regulatory burdens as U.S. firms.
Patent protection, which is essential to pharmaceutical
development, has been made stronger by providing for
statutory extensions of patent terms during periods of
FDA review and by extending U.S. patent protection to
inventions aboard U.S. spacecraft. The U.S. Patent Of-
fice, however, still refuses to grant medical patents of suf-
ficient scope to provide real protection. This lack of
proprietary protection subjects U.S. firms to increased in-
vestment risk, thereby reducing their ability to compete in
the global marketplace. Finally, patent protection must
be extended under the General Agreement on Tariffs and
Trade to allow pharmaceutical innovators protection
under the laws of developing countries. Without this type
of protection, developing countries will be denied access
to space pharmaceuticals that would otherwise benefit
them and there will be less incentive for advanced coun-
tries to develop space pharmaceuticals in the first place.
